Drugs / ledipasvir/sofosbuvir
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02605304 | Feb 2016 → Jan 2017 | HIV infectious disease, hepatitis C virus infection | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ledipasvir/sofosbuvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02605304 ↗ |
| Route | Oral | “Participants were prescribed one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.” NCT02605304 ↗ |